AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 295: H39-H47, 2008. First published May 2, 2008; doi:10.1152/ajpheart.00162.2008
0363-6135/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/H39    most recent
00162.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaul, D. K.
Right arrow Articles by Fabry, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaul, D. K.
Right arrow Articles by Fabry, M. E.

Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress

Dhananjay K. Kaul, Xiaoqin Zhang, Trisha Dasgupta, and Mary E. Fabry

Division of Hematology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York

Submitted 14 February 2008 ; accepted in final form 25 April 2008


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In sickle cell disease, nitric oxide (NO) depletion by cell-free plasma hemoglobin and/or oxygen radicals is associated with arginine deficiency, impaired NO bioavailability, and chronic oxidative stress. In transgenic-knockout sickle (BERK) mice that express exclusively human {alpha}- and βS-globins, reduced NO bioavailability is associated with induction of non-NO vasodilator enzyme, cyclooxygenase (COX)-2, and impaired NO-mediated vascular reactivity. We hypothesized that enhanced NO bioavailability in sickle mice will abate activity of non-NO vasodilators, improve vascular reactivity, decrease hemolysis, and reduce oxidative stress. Arginine treatment of BERK mice (5% arginine in mouse chow for 15 days) significantly reduced expression of non-NO vasodilators COX-2 and heme oxygenase-1. The decreased COX-2 expression resulted in reduced prostaglandin E2 (PGE2) levels. The reduced expression of non-NO vasodilators was associated with significantly decreased arteriolar dilation and markedly improved NO-mediated vascular reactivity. Arginine markedly decreased hemolysis and oxidative stress and enhanced NO bioavailability. Importantly, arteriolar diameter response to a NO donor (sodium nitroprusside) was strongly correlated with hemolytic rate (and nitrotyrosine formation), suggesting that the improved microvascular function was a response to reduced hemolysis. These results provide a strong rationale for therapeutic use of arginine in sickle cell disease and other hemolytic diseases.

sickle cell disease; microvascular regulation; vasoreactivity

ACCUMULATING EVIDENCE SHOWS reduced bioavailability of nitric oxide (NO) in human sickle cell disease (SCD) and transgenic-knockout sickle (BERK) mice (7, 10, 19). SCD is characterized by hemolytic anemia and reperfusion injury (excessive oxidant generation), both of which contribute to NO consumption and/or inactivation (1, 16, 18, 31, 36).

NO regulates vascular tone, quenches reactive oxygen species, and has anti-inflammatory effects (5, 23, 26, 31, 33). Under in vivo conditions, catalytic action of NO synthase (NOS) on the substrates arginine and oxygen results in the generation of NO and citrulline. In both human sickle cell anemia (SCA) and sickle mouse models, a preponderance of recent studies have shown depleted levels of L-arginine and NO metabolites (NOx) (8, 29, 30, 39). In SCD, arginine depletion may occur as a result of initial increase in NOS activity and excessive NO generation in response to NO consumption and/or inactivation by cell-free plasma heme and/or oxygen radicals (16, 19, 36). Additionally, conversion of arginine to ornithine by the enzyme arginase may further exacerbate arginine deficiency (16, 28). Thus the combination of hemolysis, reperfusion injury, and reduced NO bioavailability will have adverse consequences on the clinical course of SCD.

Impaired NO bioavailability in human SCD is indicated by diminished responses to sodium nitroprusside (SNP), NOS inhibitors (11, 36), and by reduced flow-mediated vasodilation (7, 11). Sickle mouse models also show attenuated responses to NO-mediated vasoactive stimuli (16, 19, 20, 32). Under the conditions of chronic hypoxia and hemolysis, induction of non-NO vasodilators, such as prostaglandins and heme oxygenase (HO)-1, may compensate for reduced NO bioavailability in SCD (11, 31). Our laboratory has previously demonstrated that reduced NO bioavailability in transgenic-knockout sickle (BERK) mice that express exclusively human {alpha}- and βS-globins is associated with COX-2 induction in microvascular endothelium (19), suggesting that COX-2 activity is a likely source of elevated PGE2 levels in sickle patients (12). Furthermore, induction of COX-2 in BERK mice is associated with dilatation of resistance vessels (arterioles), hyperperfusion, and hypotension (19). Likewise, human SCD is characterized by hyperperfusion and reduced peripheral resistance (3, 25). Thus activation of non-NO vasodilator mechanisms probably compensates for NO deficiency and helps maintain optimal oxygen delivery in the face of chronic anemia.

As NO has anti-inflammatory properties, reduced NO bioactivity in sickle patients and transgenic sickle mice will contribute to the reported inflammatory effects and increased oxidant generation (1, 14). NO deficiency in BERK mice results in markedly greater oxidative stress, as evidenced by excessive oxygen radical generation, lipid peroxidation, and reduced activity of antioxidants (1, 5). Oxygen radicals can inactivate NO (1, 16) and are implicated in hemolysis (13, 42). Oxidative stress is significantly ameliorated by arginine supplementation (5), and treatment with NO donors can alleviate reperfusion injury (15), in accordance with anti-inflammatory effect of NO (22). In contrast, NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) results in marked inflammatory response (5, 23).

We hypothesize that replenishment of NO in sickle mice will abate activity of non-NO vasodilators, improve vascular tone and responses, decrease hemolysis, and enhance NO bioavailability. Here, we show that arginine supplementation of BERK mice decreases expression of non-NO vasodilators COX-2 and HO-1, improves microvascular function, and reduces hemolysis and oxidative stress. Importantly, we show that the improved microvascular function following arginine supplementation is a response to reduced hemolysis and oxidative stress.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Transgenic Mice

Transgenic-knockout sickle (BERK) mice, expressing exclusively human {alpha}- and βS-globins and generated by Paszty et al. (35), were bred at Albert Einstein College of Medicine, as described (35, 40). C57BL/6J and BERK hemizygous mice (BERK-Hemi mice) were used as controls. BERK-Hemi mice are homozygous for the {alpha}-knockout, hemizygous for the β-knockout, and hemizygous for the BERK-transgene and express 100% {alpha}H, 15% βS, and 85% mouse β-globin. Globin composition was determined by HPLC (9). BERK mice were backcrossed for eight or more generations with C57BL/6J mice. BERK mice are characterized by anemia, significantly decreased hematocrit (Hct), and increased reticulocyte counts compared with control mice (Table 1).


View this table:
[in this window]
[in a new window]

  		Table 1. Hematological parameters in C57BL, BERK-Hemi, and BERK mice: effect of arginine

 
C57BL and BERK-Hemi mice were maintained on a standard diet and water ad libitum. Sickle mice were maintained on "sickle chow" developed by Paszty et al. (35) without added arginine (Purina Mills, St. Louis, MO). All experimental protocols were approved by the institutional animal studies committee.

Arginine Supplementation

C57BL/6J controls (n = 40), BERK (n = 41), and BERK-Hemi (n = 53) mice, weighing ~25–30 g (4–6 mo old), were supplemented with 5% arginine in mouse chow (Harlan Teklad, Madison, WI) for 15 days. The untreated controls received mouse chow without arginine.

Western Blots

Cremaster tissue lysates were prepared as described (19), and protein concentration was determined at 320 nm. Western blots were performed using 7.5% SDS-PAGE [endothelial NOS (eNOS)], 10% SDS-PAGE (COX-1, COX-2, and HO-1), and a 4–20% linear gradient SDS-PAGE (nitrotyrosine). The membranes were incubated in blocking buffer with antibodies to eNOS (Transduction Laboratory, Lexington, KY; 1:2,000); COX-1 (Santa Cruz Biotechnology; 1:500), COX-2 (Cayman Chemical, Ann Arbor, MI; 1:1,000); HO-1 (Stressgen, Victoria, BC, Canada; 1:3,000); and nitrotyrosine (clone 1A5; Upstate Biotechnology, Lake Placid, NY; 1:800). Incubation with a primary antibody was followed by horseradish peroxidase-conjugated antibody, as described (19). To ascertain equal loading of samples, the stripped membranes were reincubated with goat anti-actin antibody, followed by incubation with anti-goat IgG-horseradish peroxidase secondary antibody. The specific proteins were detected by enhanced chemiluminescence (Dupont, Wilmington, DE). The protein bands on the developed film were quantified by ImageQuant software (Molecular Dynamics, Sunnyvale, CA).

Microcirculatory Studies

Mice were anesthetized intraperitoneally with 10% urethane and 2% {alpha}-chloralose in saline (5 ml/kg), tracheostomized, the right jugular vein was cannulated for infusion of vasoactive substances, and the left carotid artery was cannulated for monitoring arterial pressure. In vivo microscopic observations were made in the transilluminated open cremaster muscle preparation, prepared according to the method of Baez (2), with modifications as described (17).

Vessel luminal diameter was measured online in A2, A3, and A4 arterioles using an image-shearing device (model 907, Instruments for Physiology and Medicine, San Diego, CA). Wall shear rates and volumetric flow (Q) were calculated from vessel diameters and mean flow velocity (centerline red cell velocity/1.6), as described (19).

Arteriolar responses to topical application of acetylcholine (ACh; Sigma, St. Louis, MO) (10–6 M) and SNP (Sigma, St. Louis, MO) (10–6 M) were determined in controls and BERK mice, as described (19). In separate experiments, mean arterial pressure (MAP) response to the infusion of L-NAME (Sigma/Aldrich) was evaluated in controls and BERK mice. L-NAME (20 mg/kg) was infused intravenously over 10 min, and MAP was measured after 20 min.

Measurement of Hemolysis and Hematological Parameters

For plasma-free hemoglobin, blood samples were drawn from the abdominal aorta, and determinations were made using a tetramethyl-benzidine-based assay kit (Catachem, Bridgeport, CT) that measures plasma-free hemoglobin and other heme-containing proteins present in plasma. Blood samples obtained from tail were analyzed for the mean corpuscular hemoglobin (MCH) and percent reticulocytes using the Bayer Advia 120 (Tarrytown, NY). Hct was measured using a microhematocrit centrifuge (MicroHematocrit, Damon/IEF Division, Needham Heights, MA).

Plasma NOx Determination

Total NOx concentration in plasma was determined by nitrate/nitrite colorimetric assay kit (Cayman Chemical, Ann Arbor, MI) using manufacturer's instructions (5).

Amino Acid Analysis

Plasma obtained from heparinized blood was stored frozen at –80°C. Samples were shipped on dry ice to the Molecular Structure Facility at the University of California at Davis. On receipt, the samples were centrifuged for 15 min at 4°C and deproteinized with 10% sulfasalicylic acid. Fifty microliters of sample were then loaded onto a Beckman 6300 Amino Acid Analyzer (Beckman Coulter, Fullerton, CA) using lithium-citrate-based ion exchange chromatography, followed by post-column ninhydrin derivatization for separation of amino-containing components.

Plasma PGE2 Determination

Plasma was collected from heparinized blood, and PGE2 was determined using PGE metabolite enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI).

Statistical Analysis

Comparisons were made using Student's t-test. Where tests for normality failed, or Bartlett's test for homogeneity of variance showed significant difference in the standard deviations, nonparametric tests, such as Kruskal-Wallis test for ANOVA or the Wilcoxon two-sample test, were used. P < 0.05 was considered significant.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
In the present studies, we evaluated the effect of arginine on vasodilator enzymes and microvascular parameters in the cremaster muscle microcirculatory bed of sickle mice. In addition, we measured cell-free plasma hemoglobin and oxidative stress (i.e., nitrotyrosine).

Arginine Has No Effect on eNOS Expression, But Reduces Expression of Non-NO Vasodilators

eNOS. Among untreated groups, eNOS expression (eNOS-to-actin ratio) in BERK and BERK-Hemi mice showed no significant differences compared with control C57BL mice (n = 3 each). Arginine supplementation caused 52 and 31% decreases in eNOS expression in BERK-Hemi and BERK mice, respectively (P < 0.001 and <0.25) (Fig. 1A).


Figure 1
View larger version (45K):
[in this window]
[in a new window]

  		Fig. 1. Effect of arginine on endothelial nitric oxide synthase (eNOS), COX-2, COX-1, and heme oxygenase-1 (HO-1) expression. A: arginine had caused 52 and 31% decreases in eNOS expression, respectively, in BERK-hemizygous (Hemi) and BERK mice. B: arginine resulted in distinct decreases in COX-2 expression in BERK-Hemi and BERK mice. C: arginine had no appreciable effect on COX-2 expression in C57BL mice. D: COX-1 expression showed no changes after arginine treatment. E: arginine markedly decreased in HO-1 expression in BERK mice.

 
Non-NO Vasodilators

COX enzymes. Western blots (Fig. 1, B and C) and densitometric analysis (Fig. 2A) revealed that, among untreated groups (n = 3 each), COX-2 expression showed approximately fourfold increase in BERK mice (P < 0.01) and 2.8-fold-increase in BERK-Hemi mice (P < 0.05) compared with C57BL mice. Arginine had no effect on COX-2 expression in C57BL mice, but caused 52 and 43% decreases in COX-2 expression in BERK-Hemi and BERK mice, respectively (P < 0.01 and P < 0.05 vs. respective untreated controls, n = 3 each; Figs. 1, B and C, and Fig. 2A). Notably, the expression of constitutively expressed COX-1 showed no differences among untreated or arginine-treated groups (Fig. 1D).


Figure 2
View larger version (12K):
[in this window]
[in a new window]

  		Fig. 2. Densitometric analysis of COX-2 expression and plasma prostaglandin E2 (PGE2) levels. A: COX-2 expression was elevated in untreated groups of BERK-Hemi and BERK mice (*P < 0.05 and **P < 0.01, respectively), with BERK mice showing the maximal increase. Arginine caused a markedly reduced expression of COX-2 in BERK-Hemi and BERK mice (52 and 43% decreases, respectively, +P < 0.01 and ++P < 0.038). B: untreated BERK-Hemi and BERK mice showed greater PGE2 levels compared with C57BL mice (*P < 0.05 and **P < 0.0001, respectively). Arginine caused marked 56% decrease in BERK mice (+P < 0.004 vs. untreated BERK).

 
Plasma PGE2 levels. As shown in Fig. 2B, the overall pattern of PGE2 levels followed the level of COX-2 expression depicted in Fig. 2A. COX-1 expression in BERK mice was not different from that in C57BL or BERK-Hemi mice, implying that the marked increase in PGE2 levels in BERK mice was due to COX-2 induction. Consistent with its effect on COX-2 expression (Fig. 2A), arginine caused 56% decrease in PGE2 levels in BERK mice (means ± SE: from 1,225 ± 72 to 536 ± 130 pg/ml, P < 0.004), but had no effect on PGE2 levels in C57BL and BERK-Hemi mice.

HO-1. In three BERK mice examined, HO-1 expression showed variable increases (2.3-, 4.2-, and 11.6-fold) compared with the averaged control values (Fig. 1E). Arginine had no appreciable effect on HO-1 expression in C57BL mice. Importantly, arginine treatment of BERK mice resulted in marked 42–45% reduction in HO-1 expression. In BERK-Hemi mice (Fig. 1E), HO-1 expression was elevated by 7.6-fold, which was reduced by 40% after arginine treatment.

Arginine Improves Microvascular Parameters in Sickle (BERK) Mice

Arteriolar diameters. Consistent with our laboratory's previous studies (19), BERK mice (n = 4) showed significant 28.4–42.5% dilation of cremasteric arterioles (branching orders: A2, A3, and A4) compared with controls (P < 0.01, n = 4; Fig. 3A). Arginine caused 20–42% diameter increases in the arterioles in C57BL (P < 0.01) and BERK-Hemi mice (P < 0.05–0.01, n = 4). In contrast, in BERK mice (n = 6), arginine resulted in a significant decrease in the diameter of A2 arterioles (P < 0.003), but had no effect on A3 and A4 diameters. It should be noted that the postarginine arteriolar diameters in each group were remarkably similar for any given arteriolar order, as depicted by horizontal lines in Fig. 3A.


Figure 3
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 3. Effect of arginine on the arteriolar diameter (branching orders: A2, A3, and A4) and flow parameters in A2 arterioles in the cremaster microcirculation. A: in C57BL and BERK-Hemi mice, arginine caused diameter increases in all arteriolar orders, whereas, in BERK mice, arginine caused either a decrease (A2 arterioles) or had no effect on the diameter. The postarginine values in each group were strikingly similar, as indicated by horizontal lines. B: arginine resulted in increased wall shear rates in BERK mice. C: the reduced A2 diameter in arginine-treated BERK mice was accompanied by reduced volumetric flow (Q), which was in contrast to the increase in Q in controls. *P < 0.05–0.001 vs. prearginine (untreated) values. +P < 0.01 vs. untreated C57BL mice.

 
Hemodynamic parameters. The effect of arginine on microvascular flow parameters was evaluated in A2 arterioles. In particular, the reduction in the A2 diameter in arginine-treated BERK mice caused 17.5% increase (P < 0.01) in the wall shear rate (s–1) (Fig. 3B). As previously reported (3), untreated BERK mice also showed maximal Q (nl/s) in A2 arterioles compared with control groups (Fig. 3C). Likewise, A2 diameter increase in arginine-treated C57BL and BERK-Hemi mice was associated with a greater Q (P < 0.01 and <0.05 vs. respective untreated controls); the resulting Q was not different from that in untreated BERK mice. In contrast, in arginine-treated BERK mice, A2 diameter decrease resulted in 27% decline in Q compared with the untreated group (P < 0.027), indicating a trend toward normalization (Fig. 3C).

Arginine Improves Vascular Reactivity to NO-Mediated Vasoactive Stimuli

Response to ACh, an endothelium-dependent vasodilator. Topical ACh (10–6 M) caused 76.6 and 73.3% increases, respectively, in arteriolar (A3) diameters (means ± SE) of untreated C57BL control (24.1 ± 2.2 to 42.4 ± 4.0 µm, P < 0.001, n = 5) and BERK-Hemi mice (22.6 ± 3.0 to 37.6 ± 3.2 µm, P < 0.001, n = 5) (Fig. 4A). In contrast, untreated BERK mice showed an attenuated response to ACh, as revealed by only a 7.3% increase in the arteriolar diameter (29.2 ± 2.3 to 32.1 ± 2.8 µm, P < 0.01, n = 5), in agreement with our laboratory's previous findings (19). Arginine had no significant effect on arteriolar responses to ACh in C57BL and BERK-Hemi mice. In contrast, ACh caused 43.5% increase in the arteriolar diameter of arginine-treated BERK mice (32.7 ± 2.6 to 47.0 ± 4.0 µm, P < 0.0001; Fig. 4A).


Figure 4
View larger version (19K):
[in this window]
[in a new window]

  		Fig. 4. Effect of arginine on vascular responses. A and B: attenuated response of arterioles in BERK mice to ACh and SNP. Arginine-treated BERK mice showed markedly improved responses to acetylcholine (ACh) and sodium nitroprusside (SNP) (*P < 0.00001 vs. C57BL and BERK-Hemi mice, +P < 0.00001 vs. untreated BERK mice). C: baseline mean arterial pressure (MAP) in untreated BERK-Hemi and BERK mice was significantly lower than in C57BL mice (*P < 0.005 and **P < 0.0001, respectively). In contrast to significant increases in untreated C57BL and BERK-Hemi mice (+P < 0.01 and ++P < 0.05, respectively), NG-nitro-L-arginine methyl ester (L-NAME) caused attenuated response in untreated BERK mice, but resulted in 43% increase in MAP in arginine (Arg)-treated BERK mice (#P < 0.001).

 
Response to SNP, a NO donor. As shown in Fig. 4B, topical SNP (10–6 M) caused 81.1 and ~65% increases in arteriolar (A3) diameters, respectively, in untreated C57BL controls (23.6 ± 2.1 to 42.3 ± 3.6 µm, P < 0.001, n = 5) and BERK-Hemi mice (20.0 ± 2.5 to 32.7 ± 3.5 µm, P < 0.0001, n = 5). In contrast, untreated BERK mice showed distinctly blunted response, as evidenced by only 15% increase in the diameter (29.4 ± 2.6 to 33.3 ± 2.2 µm, n = 5, P < 0.00001 vs. C57BL and BERK-Hemi mice), which is consistent with our laboratory's reported findings (19). In marked contrast, SNP caused ~60% increase in arteriolar diameters in arginine-treated BERK mice (30.5 ± 2.3 to 48.2 ± 4.4 µm, P < 0.002, n = 6; Fig. 4B).

Response to L-NAME. To investigate the effect of arginine on NOS activity, we measured the response of the MAP to intravenous infusion of L-NAME. As depicted in Fig. 4C, L-NAME caused significant increases (133–155%) in MAP in untreated C57BL control (n = 5) and BERK-Hemi mice (n = 3) (P < 0.01 and 0.05, respectively, vs. pre-L-NAME values), but resulted in an attenuated (i.e., 14% increase) response in untreated BERK mice (n = 5). The baseline MAP in BERK mice was also markedly lower than those for C57BL and BERK-Hemi mice (each P < 0.001). Arginine had no effect in C57BL and BERK-Hemi mice. In marked contrast, L-NAME caused 43% increase in MAP in arginine-treated BERK mice (P < 0.001).

Arginine Reduces Hemolysis

As shown in Table 1, cell-free plasma hemoglobin was significantly elevated in BERK mice compared with controls (C57BL and BERK-Hemi) mice (each P < 0.001), which is comparable with our laboratory's previous studies (19). In BERK mice, arginine resulted in marked >50% decrease in plasma hemoglobin (P < 0.001), but had no significant effect in controls (Table 1). However, the reduced hemolysis in arginine-treated BERK mice was not associated with significant changes in Hct, %reticulocytes, and MCH. This is because a decrease in micromolar cell-free hemoglobin is not expected to affect millimolar whole blood hemoglobin levels, as the amount of hemoglobin in plasma is smaller by more than a factor of 1,000 than the hemoglobin present in red cells in whole blood. On the other hand, arginine caused a significant increase in Hct (P < 0.04) and a decrease in reticulocyte counts (P < 0.03) in BERK-Hemi mice. Untreated BERK mice showed lower Hct, higher reticulocyte counts, and lower MCH compared with untreated C57BL and BERK-Hemi mice, as previously reported (3).

Arginine Increases Plasma Citrulline and NOx Levels

We monitored plasma citrulline and NOx levels as measures of NO production. Plasma arginine levels (µmol/l, means ± SE) in untreated BERK mice (36 ± 8 µmol/l, n = 9) were ~58% lower than the C57BL baseline values (85 ± 5 µmol/l, P < 0.0001, n = 14). Also, as depicted in Table 2, the lowest citrulline levels were monitored in untreated BERK mice (P < 0.03 vs. untreated C57BL mice). Following arginine treatment, citrulline levels rose 67 and 51% in BERK-Hemi and BERK mice, respectively, and the increase was significant for BERK mice (P < 0.005). Notably, citrulline levels in arginine-treated BERK mice were not significantly different from the baseline values of C57BL mice. Because arginine can also be metabolized into ornithine by the enzyme arginase, we determined plasma ornithine levels (Table 2). Untreated BERK mice showed elevated plasma ornithine values compared with C57BL mice (P < 0.03), suggesting increased arginase activity in these mice. Arginine caused increases in ornithine levels in C57BL (P < 0.0001) and BERK-Hemi mice (P < 0.005), but the increase in BERK mice was not significant (Table 2).


View this table:
[in this window]
[in a new window]

  		Table 2. Effect of arginine on plasma citrulline, ornithine, and NOx levels in C57BL, BERK-Hemi, and BERK mice

 
NOx levels showed 65 and 80% decreases, respectively, in BERK-Hemi and BERK mice compared with C57BL mice (each P < 0.0001), indicating minimal NO bioavailability in BERK mice (Table 2). Arginine caused 48 and 34.5% increases in NOx levels, respectively, in C57BL and BERK-Hemi mice compared with untreated groups (P < 0.001 and P < 0.01). In contrast, arginine resulted in greater than twofold increase in NOx levels in BERK mice compared with the untreated group (P < 0.002). This is in agreement with our laboratory's earlier studies, wherein we compared NOx levels in NY1DD transgenic sickle (mild pathology) and BERK mice (but not BERK-Hemi mice) after arginine supplementation (5).

Arginine Reduces Nitrotyrosine Expression

eNOS dysfunction has been associated with enhanced peroxynitrite (ONOO–) formation in several pathological states, including BERK mice (16, 45), which reduces NO bioavailability. Hence, we examined the effect of arginine on nitrotyrosine formation, which is the result of protein nitration by ONOO–. Western blots revealed two major bands of nitrated proteins, corresponding approximately to 60 and 26 kDa (Fig. 5A). Densitometric analysis (Fig. 5, B and C) revealed that, among untreated groups, tyrosine nitration of ~60- and 26-kDa proteins was markedly increased in BERK-Hemi and BERK mice (60-kDa protein: 2.9- and 4.6-fold increase, respectively, P < 0.01; 24-kDa protein: 4- and 5.6-fold, P < 0.05 and 0.01, respectively; n = 4 each) compared with C57BL controls (n = 4). Arginine had no effect on protein nitration in C57BL mice. In marked contrast, arginine caused distinct 53–71% decreases in tyrosine nitration of the 60- and 26-kDa proteins in BERK and BERK-hemi mice (P < 0.05–0.01) (Fig. 5, B and C), indicating a decreased oxidative stress.


Figure 5
View larger version (26K):
[in this window]
[in a new window]

  		Fig. 5. Effect of arginine on nitrotyrosine formation. A: BERK mice showed maximal tyrosine nitration of both ~60- and 26-kDa proteins. Arginine caused marked decreases in tyrosine nitration of 60- and 26-kDa proteins in BERK-Hemi and BERK mice. B and C: BERK mice showed maximal tyrosine nitration of both 66- and 26-kDa nitrated proteins, i.e., 4.6- and 5.6-fold increase over C57BL mice. Arginine supplementation caused significant decreases in the nitrated proteins in both BERK-Hemi and BERK mice compared with corresponding untreated groups. *P < 0.05–0.01 vs. C57BL mice. +P < 0.05 vs. untreated BERK-Hemi mice. ++P < 0.004 vs. untreated BERK mice.

 
NO Bioactivity: the Effect of Hemolysis and Oxidative Stress

Next, we analyzed our data whether hemolysis and/or oxidative stress affected the observed arteriolar diameter response (Fig. 4B) to SNP, a NO donor, as a measure of NO bioactivity. As shown in Fig. 6A, linear regression of the data showed a strong relationship between plasma hemoglobin levels and the mean arteriolar diameter increase (%) in response to SNP. A similar strong relationship was noted when arteriolar diameter response to SNP was plotted against levels of nitrotyrosine formation (Fig. 6B). Thus untreated BERK mice with highest plasma hemoglobin (7.7 ± 0.5 µmol, see Table 1) or nitrotyrosine formation showed minimal arteriolar diameter increase in response to SNP, whereas, after arginine treatment, SNP caused a marked 60% increase in the diameter, which was associated with reduced plasma hemoglobin values (3.7 ± 0.6 µmol) and nitrotyrosine formation.


Figure 6
View larger version (14K):
[in this window]
[in a new window]

  		Fig. 6. A: relationship between arteriolar diameter response to SNP and plasma heme levels. Percent arteriolar diameter increase after topical SNP (10–6 M) was strongly correlated with plasma hemoglobin levels. B: relationship between arteriolar diameter response to SNP and nitrotyrosine formation showed a similar strong correlation between the two parameters. Data from BERK+{gamma} mice (*) are added from Kaul et al. (19) to the above regression plots to demonstrate the dependence of arteriolar diameter response to SNP on hemolytic rate and nitrotyrosine formation.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
We show that arginine supplementation of transgenic-knockout sickle (BERK) mice significantly ameliorates several manifest abnormalities. First, in this mouse model of SCD, arginine reduces the expression of non-NO vasodilator enzymes, such as COX-2 that produces PGE2 and HO-1 that produces CO. Second, the decreased expression of non-NO vasodilators is associated with reduced vasodilation and improved vascular reactivity to NO-mediated vasoactive stimuli. Finally, arginine reduces hemolysis and oxidative stress, both of which are implicated in consumption and/or inactivation of NO, as well as in altered microvascular responses.

Notably, in BERK mice, arginine significantly reduces the expression of non-NO vasodilator enzymes COX-2 and HO-1, which are likely to contribute to the altered vascular tone and reactivity in untreated BERK mice. COX-2 is induced under the conditions of chronic hypoxia and oxidative stress. ONOO– has been implicated in the induction of COX-2 (24). COX-2 induction in BERK mice is associated with severalfold increase in PGE2 production, which will contribute to vasodilation in these mice. Higher PGE2 values probably contribute to the impaired vasoreactivity in BERK mice and sickle patients (11, 12, 19). Importantly, in BERK mice, arginine reduces COX-2 expression and PGE2 levels, probably by decreasing oxidative stress. The second non-NO vasodilator enzyme HO-1, induced in response to hemolysis, hypoxia, and oxidative stress, catalyzes degradation of heme to biliverdin/bilirubin and carbon monoxide (34, 43). Hence, HO-1 is also a marker of hemolysis with vasodilatory properties via generation of carbon monoxide. In fact, the markedly reduced HO-1 expression in arginine-supplemented BERK mice is associated with decreased hemolysis. We propose that the suppression of COX-2 and HO-1 expression following arginine treatment is a consequence of increased NO bioavailability that results in improved vascular tone and reactivity.

The protective effect of arginine on microvascular regulation in BERK mice is evident by the response of resistance vessels (arterioles). Untreated BERK mice show significant arteriolar dilation, increased Q (see Fig. 3), and systemic hypotension (see Fig. 4C), which is associated with induction of non-NO vasodilator enzymes, COX-1 and HO-1. While arginine causes significant increases in arteriolar diameters in C57BL and BERK-Hemi mice, it results in a significant reduction in A2 diameters in BERK mice, accompanied by marked decrease in the flow and reduced expression of non-NO vasodilators, suggesting a trend toward normalization. Notably, the resulting arteriolar diameters after arginine supplementation are strikingly similar in controls and BERK mice, suggesting that increased NO bioavailability may contribute to vascular homeostasis in BERK mice (see Fig. 3A).

Furthermore, arginine treatment in sickle mice causes improved arteriolar diameter response to NO-mediated vasoactive stimuli. In contrast to robust vasodilatory effects of ACh and SNP in untreated control C57BL and BERK-Hemi mice, untreated BERK mice show blunted responses to these stimuli, probably due to inactivation and/or consumption of NO by oxidants and/or plasma hemoglobin (19, 36). On the other hand, reduced oxidative stress and hemolysis in arginine-treated BERK mice are accompanied by markedly improved arteriolar diameter response to ACh and SNP. The improved response to ACh indicates a greater availability of substrate arginine. Also, distinctly blunted blood pressure response in untreated BERK mice to L-NAME indicates impaired NO/NOS-mediated control of vascular tone. In contrast, in arginine-treated BERK mice, L-NAME causes marked 43% increase in blood pressure. These results show distinctly improved vascular reactivity to NO-mediated vasoactive stimuli in arginine-supplemented BERK mice.

An important finding of the present studies with implications for NO bioavailability is the pronounced >50% decrease in cell-free plasma hemoglobin in arginine-treated BERK mice (see Table 1), which is expected to reduce NO inactivation by cell-free ferrous (oxy) hemoglobin (36). Arginine may reduce hemolysis by preventing oxidative stress-induced hemolysis of red cells. Oxygen radicals have been implicated in hemolysis of red cells in several pathological states, including β-thalassemia and SCD (13, 21). Arginine therapy of sickle patients (0.1g/kg, 3 times/day for 1 mo) has been reported to increase red cell GSH, a key red cell antioxidant that may decrease red cell oxidative stress and hemolysis (27). Similarly, arginine causes significant increase in tissue GSH in BERK mice (5). The second and potentially concurring mechanism may involve inhibition of red cell Gardos channel by arginine, as reported by Romero et al. in transgenic sickle mice (39), which will reduce dense cell formation and improve red cell deformability. Arginine supplementation of sickle transgenic mice reduces plasma endothelin-1 (ET-1) levels (38). ET-1 has been shown to stimulate the Gardos channel (37), and reduction of ET-1 may partially account for the reduction in Gardos channel activity in arginine-supplemented sickle mice. In humans, administration of clotrimazole, a Gardos channel inhibitor, did not reduce plasma lactate dehydrogenase (a surrogate marker of hemolysis) significantly (4). Further work will be needed to unravel the roles of ET-1 and its receptors during arginine supplementation.

Arginine significantly decreases oxidative stress, as evidenced by reduced nitrotyrosine expression in BERK mice. Excessive generation of free oxygen radicals can result in increased OONO– formation and nitration of tyrosine residues of proteins. Although other mechanisms of nitrotyrosine formation are now recognized (41, 45), in this model, formation of superoxide and OONO– appears to be the most straightforward explanation. Also, decreased oxidative stress following arginine treatment may inhibit the reported uncoupling of eNOS (16, 45) and thereby enhance NO synthesis.

The reduced hemolysis and oxidative stress in arginine-treated BERK mice result in enhanced NO production, as indicated by greater than twofold increase in NOx levels and >50% increase in citrulline levels, the latter approaching control (C57BL) levels. On the other hand, in BERK mice, arginine does not result in significant increase in plasma ornithine, a measure of arginase activity. Although mouse red cells lack arginase, the observed increase in ornithine levels in arginine-treated control mice suggests that arginase derived from other mouse tissues, such as endothelium (6, 44), may be involved in this conversion.

Although future studies will be required to delineate the relationship between hemolytic rate and oxidative stress in terms of cause and effect, the present studies show that reducing hemolysis and oxidative stress distinctly result in improved NO bioavailability. We find that the arteriolar diameter response to SNP, a NO donor, is strongly correlated with hemolytic rate (and nitrotyrosine formation), i.e., the greater the hemolytic rate, the lesser the arteriolar diameter increase in response to SNP (see Fig. 6, A and B). Also, elevated levels of cGMP caused by HO-1 induction (32) in response to excess plasma heme may contribute to the blunted vasodilator effect of SNP in BERK mice. The reduced hemolysis in arginine-treated BERK mice is expected to reduce NO inactivation and result in a greater response to SNP.

Although pharmacokinetics of arginine supplementation may vary among mammalian species (42), the increased NO bioavailability after arginine treatment, as noted in our studies, is more compatible with results obtained in sickle patients, wherein arginine was orally administered at a dose of 0.1 g/kg, three times a day (27, 29).

In conclusion, we show for the first time that arginine exerts a range of protective effects in sickle mice, which include improved microvascular function, reduced expression of non-NO vasodilators, decreased hemolysis and oxidative stress, and increased NO bioavailability. These results demonstrate that increasing NO bioavailability by therapeutic agents such as arginine is a promising strategy in the management of SCD.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by National Institutes of Health Grants HL-070047 and U54 38655.


   ACKNOWLEDGMENTS
 
We thank Sandra Suzuka for genotyping of the transgenic mice used in these studies.


   FOOTNOTES
 

Address for reprint requests and other correspondence: D. K. Kaul, Dept. of Medicine, Rm. U-917, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461 (e-mail: kaul{at}aecom.yu.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98: 15215–15220, 2001.[Abstract/Free Full Text]
  2. Baez S. An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res 5: 384–394, 1973.[CrossRef][Web of Science][Medline]
  3. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 97: 1584–1589, 2001.[Abstract/Free Full Text]
  4. Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, Alper SL, Platt OS. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease [see comments]. J Clin Invest 97: 1227–1234, 1996.[Web of Science][Medline]
  5. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 41: 1771–1780, 2006.[CrossRef][Web of Science][Medline]
  6. de Bono JP, Warrick N, Bendall JK, Channon KM, Alp NJ. Radiochemical HPLC detection of arginine metabolism: measurement of nitric synthesis and arginase activity in vascular tissue. Nitric Oxide 16: 1–9, 2007.[CrossRef][Web of Science][Medline]
  7. Eberhardt RT, McMahon L, Duffy SJ, Steinberg MH, Perrine SP, Loscalzo J, Coffman JD, Vita JA. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol 74: 104–111, 2003.[CrossRef][Web of Science][Medline]
  8. Enwonwu CO. Increased metabolic demand for arginine in sickle cell anemia. Med Sci Res 17: 997–998, 1989.
  9. Fabry ME, Suzuka SM, Weinberg RS, Lawrence C, Factor SM, Gilman JG, Costantini F, Nagel RL. Second generation knockout sickle mice: the effect of HbF. Blood 97: 410–418, 2001.[Abstract/Free Full Text]
  10. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program 51–57, 2005.
  11. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO III. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107: 271–278, 2003.[Abstract/Free Full Text]
  12. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 92: 2551–2555, 1998.[Abstract/Free Full Text]
  13. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 70: 1253–1259, 1982.[Web of Science][Medline]
  14. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11: 129–151, 2004.[CrossRef][Web of Science][Medline]
  15. Hoffman A, Goldstein S, Samuni A, Borman JB, Schwalb H. Effect of nitric oxide and nitroxide SOD-mimic on the recovery of isolated rat heart following ischemia and reperfusion. Biochem Pharmacol 66: 1279–1286, 2003.[CrossRef][Web of Science][Medline]
  16. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109: 3088–3098, 2007.[Abstract/Free Full Text]
  17. Kaul DK, Fabry ME, Costantini F, Rubin EM, Nagel RL. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 96: 2845–2853, 1995.[Web of Science][Medline]
  18. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice [see comments]. J Clin Invest 106: 411–420, 2000.[Web of Science][Medline]
  19. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest 114: 1136–1145, 2004.[CrossRef][Web of Science][Medline]
  20. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol 278: H1799–H1806, 2000.[Abstract/Free Full Text]
  21. Kruckeberg WC, Doorenbos DI, Brown PO. Genetic differences in hemoglobin influence on erythrocyte oxidative stress hemolysis. Blood 70: 909–914, 1987.[Abstract/Free Full Text]
  22. Kubes P, Payne D, Grisham MB, Jourd-Heuil D, Fox-Robichaud A. Inhaled NO impacts vascular but not extravascular compartments in postischemic peripheral organs. Am J Physiol Heart Circ Physiol 277: H676–H682, 1999.[Abstract/Free Full Text]
  23. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651–4655, 1991.[Abstract/Free Full Text]
  24. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 93: 15069–15074, 1996.[Abstract/Free Full Text]
  25. Lonsdorfer J, Bogui P, Otayeck A, Bursaux E, Poyart C, Cabannes R. Cardiorespiratory adjustments in chronic sickle cell anemia. Bull Eur Physiopathol Respir 19: 339–344, 1983.[Web of Science][Medline]
  26. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, pharmacology. Pharmacol Rev 43: 109–142, 1991.[Web of Science][Medline]
  27. Morris CA, Suh J, Vichinsky EP, Klings ES, Steinberg M, Shigenaga M, Ames BN, Gladwin MT, Kato GJ. Oral arginine increases erythrocyte glutathione levels in sickle cell disease: implications for pulmonary hypertension. In: Proceedings of the 35th Anniversary Convention of the national Sickle Cell Disease Program and the Sickle Cell Disease Association of America, Washington, DC, September 17, 2007.
  28. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294: 81–90, 2005.[Abstract/Free Full Text]
  29. Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, Styles LA. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 111: 498–500, 2000.[CrossRef][Web of Science][Medline]
  30. Morris CR, Morris SM Jr, Hagar W, van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168: 63–69, 2003.[Abstract/Free Full Text]
  31. Nath KA, Katusic ZS, Gladwin MT. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation 11: 179–193, 2004.[CrossRef][Web of Science][Medline]
  32. Nath KA, Shah V, Haggard JJ, Croatt AJ, Smith LA, Hebbel RP, Katusic ZS. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 279: R1949–R1955, 2000.[Abstract/Free Full Text]
  33. Ogawa T, Nussler AK, Tuzuner E, Neuhaus P, Kaminishi M, Mimura Y, Beger HG. Contribution of nitric oxide to the protective effects of ischemic preconditioning in ischemia-reperfused rat kidneys. J Lab Clin Med 138: 50–58, 2001.[CrossRef][Web of Science][Medline]
  34. Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 278: C92–C101, 2000.[Abstract/Free Full Text]
  35. Paszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease [see comments]. Science 278: 876–878, 1997.[Abstract/Free Full Text]
  36. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, III, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383–1389, 2002.[CrossRef][Web of Science][Medline]
  37. Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 99: 357–603, 2002.[Abstract/Free Full Text]
  38. Romero JR, Rivera A, Muniz A, Nagel RL, Fabry ME. Arginine diet for sickle transgenic mice reduces endothelin-1-stimulated Gardos channel activity. Blood 118: 996A, 2007.
  39. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 99: 1103–1108, 2002.[Abstract/Free Full Text]
  40. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science 278: 873–876, 1997.[Abstract/Free Full Text]
  41. Thomas DD, Espey MG, Vitek MP, Miranda KM, Wink DA. Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2– reaction. Proc Natl Acad Sci USA 99: 12691–12696, 2002.[Abstract/Free Full Text]
  42. Wu G, Bazer FW, Cudd TA, Jobgen WS, Kim SW, Lassala A, Li P, Matis JH, Meininger CJ, Spencer TE. Pharmacokinetics and safety of arginine supplementation in animals. J Nutr 137: 1673S–1680S, 2007.[Abstract/Free Full Text]
  43. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel Christou H, Kourembanas S, Lee ME. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 103: R23–R29, 1999.[Medline]
  44. Yu H, Yoo PK, Aguirre CC, Tsoa RW, Kern RM, Grody WW, Cederbaum SD, Iyer RK. Widespread expression of arginase I in mouse tissues: biochemical and physiological implications. J Histochem Cytochem 51: 1151–1160, 2003.[Abstract/Free Full Text]
  45. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817–826, 2002.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. L. Krajewski, L. L. Hsu, and M. T. Gladwin
The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H4 - H7.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
C. R. Morris
Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia
Hematology, January 1, 2008; 2008(1): 177 - 185.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
G. J. Kato
Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I
Hematology, January 1, 2008; 2008(1): 186 - 192.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/H39    most recent
00162.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaul, D. K.
Right arrow Articles by Fabry, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaul, D. K.
Right arrow Articles by Fabry, M. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.